Cargando…
External Validation and User Experiences of the ProPal-COPD Tool to Identify the Palliative Phase in COPD
BACKGROUND: Difficulty predicting prognosis is a major barrier to timely palliative care provision for patients with COPD. The ProPal-COPD tool, combining six clinical indicators and the Surprise Question (SQ), aims to predict 1-year mortality as a proxy for palliative care needs. It appeared to be...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792220/ https://www.ncbi.nlm.nih.gov/pubmed/36579356 http://dx.doi.org/10.2147/COPD.S387716 |
_version_ | 1784859588004151296 |
---|---|
author | Broese, Johanna M C van der Kleij, Rianne M J J Verschuur, Els M L Kerstjens, Huib A M Bronkhorst, Ewald M Chavannes, Niels H Engels, Yvonne |
author_facet | Broese, Johanna M C van der Kleij, Rianne M J J Verschuur, Els M L Kerstjens, Huib A M Bronkhorst, Ewald M Chavannes, Niels H Engels, Yvonne |
author_sort | Broese, Johanna M C |
collection | PubMed |
description | BACKGROUND: Difficulty predicting prognosis is a major barrier to timely palliative care provision for patients with COPD. The ProPal-COPD tool, combining six clinical indicators and the Surprise Question (SQ), aims to predict 1-year mortality as a proxy for palliative care needs. It appeared to be a promising tool for healthcare providers to identify patients with COPD who could benefit from palliative care. OBJECTIVE: To externally validate the ProPal-COPD tool and to assess user experiences. METHODS: Patients admitted with an acute exacerbation COPD were recruited across 10 hospitals. Demographics, clinical characteristics and survival status were collected. Sensitivity, specificity, positive and negative predictive values of the tool using two cut-off values were calculated. Also, predictive properties of the SQ were calculated. In monitoring meetings and interviews, healthcare providers shared their experiences with the tool. Transcripts were deductively coded using six user experience domains: Acceptability, Satisfaction, Credibility, Usability, User-reported adherence and Perceived impact. RESULTS: A total of 523 patients with COPD were included between May 2019 and August 2020, of whom 100 (19.1%) died within 12 months. The ProPal-COPD tool had an AUC of 0.68 and a low sensitivity (55%) and moderate specificity (74%) for predicting 1-year all-cause mortality. Using a lower cut-off value, sensitivity was higher (74%), but specificity lower (46%). Sensitivity and specificity of the SQ were 56% and 73%, respectively (AUC 0.65). However, healthcare providers generally appreciated using the tool because it increased awareness of the palliative phase and provided a shared understanding of prognosis, although they considered its outcome not always correct. CONCLUSION: The accuracy of the ProPal-COPD tool to predict 1-year mortality is limited, although screening patients with its indicators increases healthcare providers’ awareness of palliative care needs and encourages them to timely initiate appropriate care. |
format | Online Article Text |
id | pubmed-9792220 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-97922202022-12-27 External Validation and User Experiences of the ProPal-COPD Tool to Identify the Palliative Phase in COPD Broese, Johanna M C van der Kleij, Rianne M J J Verschuur, Els M L Kerstjens, Huib A M Bronkhorst, Ewald M Chavannes, Niels H Engels, Yvonne Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: Difficulty predicting prognosis is a major barrier to timely palliative care provision for patients with COPD. The ProPal-COPD tool, combining six clinical indicators and the Surprise Question (SQ), aims to predict 1-year mortality as a proxy for palliative care needs. It appeared to be a promising tool for healthcare providers to identify patients with COPD who could benefit from palliative care. OBJECTIVE: To externally validate the ProPal-COPD tool and to assess user experiences. METHODS: Patients admitted with an acute exacerbation COPD were recruited across 10 hospitals. Demographics, clinical characteristics and survival status were collected. Sensitivity, specificity, positive and negative predictive values of the tool using two cut-off values were calculated. Also, predictive properties of the SQ were calculated. In monitoring meetings and interviews, healthcare providers shared their experiences with the tool. Transcripts were deductively coded using six user experience domains: Acceptability, Satisfaction, Credibility, Usability, User-reported adherence and Perceived impact. RESULTS: A total of 523 patients with COPD were included between May 2019 and August 2020, of whom 100 (19.1%) died within 12 months. The ProPal-COPD tool had an AUC of 0.68 and a low sensitivity (55%) and moderate specificity (74%) for predicting 1-year all-cause mortality. Using a lower cut-off value, sensitivity was higher (74%), but specificity lower (46%). Sensitivity and specificity of the SQ were 56% and 73%, respectively (AUC 0.65). However, healthcare providers generally appreciated using the tool because it increased awareness of the palliative phase and provided a shared understanding of prognosis, although they considered its outcome not always correct. CONCLUSION: The accuracy of the ProPal-COPD tool to predict 1-year mortality is limited, although screening patients with its indicators increases healthcare providers’ awareness of palliative care needs and encourages them to timely initiate appropriate care. Dove 2022-12-22 /pmc/articles/PMC9792220/ /pubmed/36579356 http://dx.doi.org/10.2147/COPD.S387716 Text en © 2022 Broese et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Broese, Johanna M C van der Kleij, Rianne M J J Verschuur, Els M L Kerstjens, Huib A M Bronkhorst, Ewald M Chavannes, Niels H Engels, Yvonne External Validation and User Experiences of the ProPal-COPD Tool to Identify the Palliative Phase in COPD |
title | External Validation and User Experiences of the ProPal-COPD Tool to Identify the Palliative Phase in COPD |
title_full | External Validation and User Experiences of the ProPal-COPD Tool to Identify the Palliative Phase in COPD |
title_fullStr | External Validation and User Experiences of the ProPal-COPD Tool to Identify the Palliative Phase in COPD |
title_full_unstemmed | External Validation and User Experiences of the ProPal-COPD Tool to Identify the Palliative Phase in COPD |
title_short | External Validation and User Experiences of the ProPal-COPD Tool to Identify the Palliative Phase in COPD |
title_sort | external validation and user experiences of the propal-copd tool to identify the palliative phase in copd |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792220/ https://www.ncbi.nlm.nih.gov/pubmed/36579356 http://dx.doi.org/10.2147/COPD.S387716 |
work_keys_str_mv | AT broesejohannamc externalvalidationanduserexperiencesofthepropalcopdtooltoidentifythepalliativephaseincopd AT vanderkleijriannemjj externalvalidationanduserexperiencesofthepropalcopdtooltoidentifythepalliativephaseincopd AT verschuurelsml externalvalidationanduserexperiencesofthepropalcopdtooltoidentifythepalliativephaseincopd AT kerstjenshuibam externalvalidationanduserexperiencesofthepropalcopdtooltoidentifythepalliativephaseincopd AT bronkhorstewaldm externalvalidationanduserexperiencesofthepropalcopdtooltoidentifythepalliativephaseincopd AT chavannesnielsh externalvalidationanduserexperiencesofthepropalcopdtooltoidentifythepalliativephaseincopd AT engelsyvonne externalvalidationanduserexperiencesofthepropalcopdtooltoidentifythepalliativephaseincopd |